TERN / Terns Pharmaceuticals: Early-Stage Biopharma Worthy Of Your Attention

Terns Pharmaceuticals stock is down 15% in the past 10 months, despite bullish articles following a bearish prediction. The company initially planned more_horizontal

TERN's TERN-701 is being developed for Chronic Myeloid Leukemia (CML), but NVS' Scemblix is similar and already approved. TERN-701 may offer benefits more_horizontal

FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage more_horizontal

Terns Pharmaceuticals has a promising pipeline with potential best-in-class therapies for obesity and NASH. Upcoming data readouts for TERN-601 and TE more_horizontal

Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal

Terns Pharmaceuticals released fourth-quarter and full-year earnings on Monday. The company is looking at therapies to treat various oncology targets, more_horizontal

TERN has a growing pipeline of early-stage assets against validated targets. TERN's internal discovery team has been productive at developing small mo more_horizontal

Insiders spent millions on these penny stocks to buy in August. The post 4 Penny Stocks Insiders Spent Millions To Buy In August 2022 appeared first o more_horizontal